Abivax S.A. ABVX
Abivax S.A. (Nasdaq: ABVX) is a GI/hepatology drug developer. Its lead program, obefazimod, is in Phase 3 for moderately to severely active ulcerative colitis. Its next catalyst on record is miR-124 platform: selection of follow-on compound (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: miR-124 platform — selection of follow-on compound (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| obefazimod | ulcerative colitis (ABTECT induction + maintenance) | small molecule | Phase 3 |
| obefazimod | Crohn's disease (ENHANCE-CD) | small molecule | Phase 2 |
| obefazimod + etrasimod combination | inflammatory bowel disease | small molecule | Pre-clinical |
| miR-124 follow-on compound | IBD | small molecule | Pre-clinical |
Recent results and decisions
- Sep 21, 2026n/a Chris Rabbat appointed Chief Medical Officer succeeding Fabio Cataldi, and Tim Kelly appointed Chief Technical Officer effective immediately.
Chris Rabbat, Ph.D., who has led Global Medical Affairs since 2023, will succeed Dr. Cataldi as Chief Medical Officer
Filing - Sep 21, 2026n/a Abivax expects to submit NDA to the U.S. FDA for obefazimod in moderately to severely active ulcerative colitis in the fourth quarter of 2026.
We believe we remain on track to submit our NDA to the U.S. FDA in the fourth quarter of 2026.
Filing - Jul 6, 2026n/a Abivax completed an underwritten public offering of 7,360,000 ADSs at $125.00 per ADS, raising net proceeds of approximately $874.1 million.
The net proceeds, after deducting underwriting commissions and estimated offering expenses, were approximately $874.1 million, equivalent to approximately €767.1 million.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.